Logo image of RVPH

REVIVA PHARMACEUTICALS HOLDI (RVPH) Stock Fundamental Analysis

USA - Nasdaq - NASDAQ:RVPH - US76152G1004 - Common Stock

0.3504 USD
+0 (+0.11%)
Last: 1/15/2026, 8:15:01 PM
0.342 USD
-0.01 (-2.4%)
After Hours: 1/15/2026, 8:15:01 PM
Fundamental Rating

1

Taking everything into account, RVPH scores 1 out of 10 in our fundamental rating. RVPH was compared to 190 industry peers in the Pharmaceuticals industry. The financial health of RVPH is average, but there are quite some concerns on its profitability. RVPH is valued expensive and it does not seem to be growing.


Dividend Valuation Growth Profitability Health

0

1. Profitability

1.1 Basic Checks

  • RVPH had negative earnings in the past year.
  • In the past year RVPH has reported a negative cash flow from operations.
  • RVPH had negative earnings in 4 of the past 5 years.
  • RVPH had a negative operating cash flow in each of the past 5 years.
RVPH Yearly Net Income VS EBIT VS OCF VS FCFRVPH Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2019 2020 2021 2022 2023 2024 0 -10M -20M -30M

1.2 Ratios

  • RVPH's Return On Assets of -158.77% is on the low side compared to the rest of the industry. RVPH is outperformed by 87.37% of its industry peers.
  • RVPH has a Return On Equity of -500.18%. This is amonst the worse of the industry: RVPH underperforms 80.53% of its industry peers.
Industry RankSector Rank
ROA -158.77%
ROE -500.18%
ROIC N/A
ROA(3y)-169.33%
ROA(5y)-106.82%
ROE(3y)-1567.74%
ROE(5y)-946.37%
ROIC(3y)N/A
ROIC(5y)N/A
RVPH Yearly ROA, ROE, ROICRVPH Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2019 2020 2021 2022 2023 2024 0 -1K -2K -3K

1.3 Margins

  • The Profit Margin and Operating Margin and Gross Margin are not available for RVPH so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
RVPH Yearly Profit, Operating, Gross MarginsRVPH Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2019 2020 2021 2022 2023 2024

More info and screens

4

2. Health

2.1 Basic Checks

  • RVPH has more shares outstanding than it did 1 year ago.
  • RVPH has more shares outstanding than it did 5 years ago.
  • RVPH has a worse debt/assets ratio than last year.
RVPH Yearly Shares OutstandingRVPH Yearly Shares OutstandingYearly Shares Outstanding 2019 2020 2021 2022 2023 2024 10M 20M 30M 40M
RVPH Yearly Total Debt VS Total AssetsRVPH Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2019 2020 2021 2022 2023 2024 20M 40M 60M

2.2 Solvency

  • Based on the Altman-Z score of -20.15, we must say that RVPH is in the distress zone and has some risk of bankruptcy.
  • RVPH has a Altman-Z score of -20.15. This is amonst the worse of the industry: RVPH underperforms 83.68% of its industry peers.
  • There is no outstanding debt for RVPH. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z -20.15
ROIC/WACCN/A
WACCN/A
RVPH Yearly LT Debt VS Equity VS FCFRVPH Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2019 2020 2021 2022 2023 2024 0 20M -20M 40M 60M

2.3 Liquidity

  • RVPH has a Current Ratio of 1.39. This is a normal value and indicates that RVPH is financially healthy and should not expect problems in meeting its short term obligations.
  • RVPH has a worse Current ratio (1.39) than 73.68% of its industry peers.
  • RVPH has a Quick Ratio of 1.39. This is a normal value and indicates that RVPH is financially healthy and should not expect problems in meeting its short term obligations.
  • RVPH's Quick ratio of 1.39 is on the low side compared to the rest of the industry. RVPH is outperformed by 66.84% of its industry peers.
Industry RankSector Rank
Current Ratio 1.39
Quick Ratio 1.39
RVPH Yearly Current Assets VS Current LiabilitesRVPH Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2019 2020 2021 2022 2023 2024 10M 20M 30M

More info and screens

1

3. Growth

3.1 Past

  • The Earnings Per Share has grown by an impressive 58.56% over the past year.
EPS 1Y (TTM)58.56%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%76%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

  • RVPH is expected to show quite a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 14.15% yearly.
  • No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y54.84%
EPS Next 2Y29.17%
EPS Next 3Y18.76%
EPS Next 5Y14.15%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

  • No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
RVPH Yearly Revenue VS EstimatesRVPH Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2026 2028 2029 2030 2031 2032 2033 500M 1B
RVPH Yearly EPS VS EstimatesRVPH Yearly EPS VS EstimatesYearly EPS VS Estimates 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 2033 0 1 -1 2

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

  • The Price/Earnings Ratio is negative for RVPH. In the last year negative earnings were reported.
  • Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for RVPH. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
RVPH Price Earnings VS Forward Price EarningsRVPH Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 10 20 30

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
RVPH Per share dataRVPH EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 -0.1 -0.2 -0.3 -0.4

4.3 Compensation for Growth

  • RVPH's earnings are expected to grow with 18.76% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y29.17%
EPS Next 3Y18.76%

More info and screens

0

5. Dividend

5.1 Amount

  • No dividends for RVPH!.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

REVIVA PHARMACEUTICALS HOLDI

NASDAQ:RVPH (1/15/2026, 8:15:01 PM)

After market: 0.342 -0.01 (-2.4%)

0.3504

+0 (+0.11%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)11-13
Earnings (Next)03-30
Inst Owners8.22%
Inst Owner Change-0.01%
Ins Owners3.01%
Ins Owner Change0%
Market Cap40.32M
Revenue(TTM)N/A
Net Income(TTM)-22.76M
Analysts81.54
Price Target5.87 (1575.23%)
Short Float %23.29%
Short Ratio3.57
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)16.25%
Min EPS beat(2)-6.95%
Max EPS beat(2)39.44%
EPS beat(4)3
Avg EPS beat(4)23.56%
Min EPS beat(4)-6.95%
Max EPS beat(4)39.44%
EPS beat(8)7
Avg EPS beat(8)18.04%
EPS beat(12)8
Avg EPS beat(12)-2.4%
EPS beat(16)11
Avg EPS beat(16)0.13%
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)-1.43%
EPS NQ rev (1m)6.79%
EPS NQ rev (3m)27.25%
EPS NY rev (1m)0%
EPS NY rev (3m)12.04%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 8.86
P/tB 8.86
EV/EBITDA N/A
EPS(TTM)-0.46
EYN/A
EPS(NY)-0.3
Fwd EYN/A
FCF(TTM)-0.24
FCFYN/A
OCF(TTM)-0.24
OCFYN/A
SpS0
BVpS0.04
TBVpS0.04
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -158.77%
ROE -500.18%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-169.33%
ROA(5y)-106.82%
ROE(3y)-1567.74%
ROE(5y)-946.37%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score5
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 1.39
Quick Ratio 1.39
Altman-Z -20.15
F-Score5
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)58.56%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%76%
EPS Next Y54.84%
EPS Next 2Y29.17%
EPS Next 3Y18.76%
EPS Next 5Y14.15%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y33.55%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-15.57%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-15.57%
OCF growth 3YN/A
OCF growth 5YN/A

REVIVA PHARMACEUTICALS HOLDI / RVPH FAQ

Can you provide the ChartMill fundamental rating for REVIVA PHARMACEUTICALS HOLDI?

ChartMill assigns a fundamental rating of 1 / 10 to RVPH.


What is the valuation status of REVIVA PHARMACEUTICALS HOLDI (RVPH) stock?

ChartMill assigns a valuation rating of 0 / 10 to REVIVA PHARMACEUTICALS HOLDI (RVPH). This can be considered as Overvalued.


What is the profitability of RVPH stock?

REVIVA PHARMACEUTICALS HOLDI (RVPH) has a profitability rating of 0 / 10.